Aquestive Therapeutics Inc
$ 4.21
5.51%
11 Jun - close price
- Market Cap 500,546,000 USD
- Current Price $ 4.21
- High / Low $ 4.25 / 3.96
- Stock P/E N/A
- Book Value -0.27
- EPS -0.61
- Next Earning Report 2026-08-11
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA -0.29 %
- ROE N/A %
- 52 Week High 7.55
- 52 Week Low 2.93
About
Aquestive Therapeutics, Inc., a pharmaceutical company, focuses on identifying, developing, and marketing various products to address unmet medical needs in the United States and internationally. The company is headquartered in Warren, New Jersey.
Analyst Target Price
$8.89
Quarterly Earnings
| Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2026-05-13 | 2026-03-04 | 2025-11-05 | 2025-08-11 | 2025-05-12 | 2025-03-05 | 2024-11-04 | 2024-08-06 | 2024-05-07 | 2024-03-05 | 2023-11-06 | 2023-08-07 |
| Reported EPS | -0.05 | -0.26 | -0.11 | -0.12 | -0.22 | -0.1607 | -0.11 | -0.01 | -0.17 | -0.09 | -0.03 | -0.1 |
| Estimated EPS | -0.13 | -0.13 | -0.11 | -0.17 | -0.16 | -0.1325 | -0.12 | -0.11 | -0.08 | -0.07 | -0.11 | -0.12 |
| Surprise | 0.08 | -0.13 | 0 | 0.05 | -0.06 | -0.0282 | 0.01 | 0.1 | -0.09 | -0.02 | 0.08 | 0.02 |
| Surprise Percentage | 61.5385% | -100% | 0% | 29.4118% | -37.5% | -21.283% | 8.3333% | 90.9091% | -112.5% | -28.5714% | 72.7273% | 16.6667% |
Next Quarterly Earnings
| Jun 2026 | |
|---|---|
| Reported Date | 2026-08-11 |
| Fiscal Date Ending | 2026-06-30 |
| Estimated EPS | -0.12 |
| Currency | USD |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: AQST
2026-06-10 14:09:46
Aquestive Therapeutics (AQST) shareholders strongly supported all proposals at their 2026 AGM. The meeting highlighted progress towards FDA approval and commercial launch of Anaphylm, global regulatory advancements, and ongoing pipeline development. No new material non-public information was disclosed during the Q&A session.
2026-06-04 18:40:06
Bronstein, Gewirtz & Grossman, LLC is investigating Aquestive Therapeutics, Inc. (AQST) for potential corporate wrongdoing. The firm encourages investors who purchased AQST securities before June 16, 2025, and continue to hold them, to contact them to assist in the investigation. The representation is on a contingency fee basis, meaning no upfront cost to investors.
2026-06-02 21:09:50
Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of Aquestive Therapeutics, Inc. (AQST) stockholders who purchased securities prior to June 16, 2025. The investigation focuses on possible corporate wrongdoing by Aquestive and its officers/directors. The law firm encourages affected investors to contact them for more information, noting that they operate on a contingency fee basis.
2026-05-31 11:00:00
Bronstein, Gewirtz & Grossman, LLC is investigating potential claims against Aquestive Therapeutics, Inc. (NASDAQ: AQST) for alleged corporate wrongdoing. The firm encourages stockholders who purchased Aquestive securities before June 16, 2025, and still hold them, to contact them to assist with the investigation. The investigation is conducted on a contingency fee basis, meaning no cost to investors unless successful.
2026-05-27 04:39:10
Bronstein, Gewirtz & Grossman, LLC has launched an investigation into Aquestive Therapeutics, Inc. (AQST) for potential corporate wrongdoing. The firm encourages investors who purchased Aquestive securities before June 16, 2025, and continue to hold them, to contact them to assist with the investigation. This action is part of the firm's focus on restoring investor capital and ensuring corporate accountability.
2026-05-18 18:09:26
The CEO of Aquestive Therapeutics, Daniel Barber, sold 8,257 shares of the company's common stock for a total of $35,413 on May 15, 2026. This transaction follows a 75% stock return over the past year, though the shares are down 35% year-to-date. The company recently surpassed Q1 2026 earnings expectations and analysts maintain a bullish outlook.
